The long-standing debate over just how low we can safely push low-density lipoprotein cholesterol (LDL-C) has a definitive new answer. Long-term data from the open-label extension of the landmark FOURIER trial (FOURIER-OLE) confirms that pushing LDL-C down to ultra-low levels—even below 20 mg/dL—continues to slash cardiovascular risk with absolutely no signs of long-term safety penalties.
While the connection between high LDL-C and atherosclerotic cardiovascular disease (ASCVD) is a cornerstone of modern cardiology, doctors have long wondered about the floor. Is there a point of diminishing returns for efficacy, or worse, a threshold where extreme cholesterol depletion harms neurological function, cellular integrity, or hormone synthesis?
The newly released long-term data puts those concerns to rest.
The Study Protocol
To map the long-term efficacy and safety of extreme LDL-C lowering, researchers tracked patients transitioning from the original FOURIER trial—a randomized, placebo-controlled study of the PCSK9 inhibitor evolocumab—into the FOURIER-OLE open-label extension.
- The Cohort: 6,635 patients with stable ASCVD transitioned into the extension phase, all receiving open-label evolocumab regardless of their original treatment assignment.
- The Timeline: Patients were followed for an additional median of 5 years, with some followed up to a maximum of 8.6 years when combining the parent and extension trials.
- The Metrics: Achieved LDL-C levels were calculated using an average of the first two measurements during the extension phase. Patients were stratified into five distinct cholesterol tiers to look for trends.
The Findings: The Lower, The Better
The results demonstrated a highly consistent, monotonic relationship: lower achieved LDL-C directly correlated with a lower risk of major cardiac events. Crucially, this benefit did not plateau, persisting all the way down to the lowest measured tier of under 20 mg/dL (<0.5 mmol/L).
| Achieved LDL-C Tier (mg/dL) | Patient Count (N=6,559) | Percentage of Cohort |
|---|---|---|
| < 20 | 1,604 | 24% |
| 20 to < 40 | 2,627 | 40% |
| 40 to < 55 | 1,031 | 16% |
| 55 to < 70 | 486 | 7% |
| ≥ 70 | 811 | 12% |
Even after rigorous multivariable modeling to adjust for baseline health factors, the trend remained highly statistically significant (p < 0.0001). Patients in the ultra-low tiers experienced significantly fewer events making up the primary efficacy endpoint (a composite of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalizations, or coronary revascularization).
Reassuring News on Long-Term Safety
For longevity and preventative medicine enthusiasts, the most critical takeaway from this analysis is the safety profile. Concerns have historically circulated around whether ultra-low cholesterol might provoke cognitive decline, accelerate cataract formation, or disrupt blood vessels enough to cause brain bleeds.
The long-term data from FOURIER-OLE showed no statistically significant associations between lower achieved LDL-C levels and an increased risk of any monitored safety issue. Specifically, pushing LDL-C below 20 mg/dL did not increase rates of:
- Neurocognitive or muscle-related adverse events
- New-onset diabetes
- Hemorrhagic stroke
- Cataract-related adverse events
- New or recurrent cancers
- Serious adverse events or non-cardiovascular death
Longevity Implications
For years, the cardiovascular medicine community has operated under the mantra “lower is better.” These extension data lengthen that timeline to “lower is better, for longer.”
By proving that maintaining physiological LDL-C levels akin to those of a newborn baby (<20 mg/dL) for up to 8.6 years is both safe and highly protective against heart attacks and strokes, the study provides strong justification for aggressive, early, and sustained lipid-lowering therapies in high-risk patients. When it comes to preventing the world’s number one killer, pushing cholesterol to the absolute floor appears to be a winning strategy. @adssx @CronosTempi @desertshores
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE